Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASTERPLAN: SBRT and Chemotherapy in High-Risk Pancreatic Cancer
NCT04089150Phase 2Unknown
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Oct 2019
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Locoregional Response Rate (LRR) at 12 months. Status: unknown.
02
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04089150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04089150.